Company profile: Koelis
1.1 - Company Overview
Company description
- Provider of medical imaging solutions for urologists, including KOELIS Trinity MRI/US prostate biopsy system for accurate needle guidance in prostate cancer diagnosis and treatment; OBT Fusion for prostate tracking and core location recording with precise targeting; 3D Ultrasound with motion compensation; 2nd Look Option; and transperineal and transrectal tools with 3D probes, holders, guides, and accessories.
Products and services
- 3D Ultrasound: A real-time imaging platform that automatically compensates for prostate and patient movement to preserve consistent visualization of the anatomy during imaging
- KOELIS Trinity: A clinical-grade MRI/US prostate biopsy platform that delivers accurate needle guidance for diagnosis and treatment of prostate cancer
- OBT Fusion: A precision-tracking imaging component that tracks the prostate and records each core location, enabling precise targeting of any part of the prostate during biopsy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Koelis
Day One Bio
HQ: United States
Website
- Description: Provider of targeted therapies for life-threatening diseases, including OJEMDA (tovorafenib), FDA-approved for children with BRAF-altered relapsed or progressive pediatric low-grade glioma; advancing investigational MAPK-pathway inhibitors tovorafenib and pimasertib and conducting FIREFLY-1/2 and FIRELIGHT-1 trials in brain and solid tumors with MAPK pathway aberrations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day One Bio company profile →
ECM Therapeutics
HQ: United States
Website
- Description: Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ECM Therapeutics company profile →
Lycia Therapeutics
HQ: United States
Website
- Description: Provider of lysosome-targeting chimeras (LYTAC) technology for developing therapeutics that target and degrade extracellular and membrane-bound proteins for a range of diseases. Offers the LYTAC platform and a discovery pipeline of degraders for autoimmune and inflammatory conditions and cancer, and maintains a strategic collaboration with Lilly focused on immunology and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lycia Therapeutics company profile →
ArQule
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of cancer therapeutics, employing its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, including ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArQule company profile →
TORL Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TORL Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Koelis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Koelis
2.2 - Growth funds investing in similar companies to Koelis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Koelis
4.2 - Public trading comparable groups for Koelis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →